Perplexity AI’s Bold Crypto Forecast: XRP, Solana and Ethereum Price Targets for 2025 Revealed
Artificial intelligence throws down the gauntlet with definitive year-end predictions for three major cryptocurrencies.
The Algorithmic Crystal Ball
Perplexity AI's neural networks have crunched the numbers—projecting exactly where XRP, Solana, and Ethereum will land when the calendar flips to 2026. No vague predictions here, just hard targets that'll either make traders rich or leave them rethinking their life choices.
Market Mechanics Unleashed
These aren't random guesses—the AI analyzes trading patterns, adoption metrics, and regulatory landscapes most humans would need three monitors and six espresso shots to comprehend. It spots correlations invisible to the naked eye, finding signals in the noise that typically only emerge in post-mortem analysis.
The Triple Threat Assessment
Each coin gets the full diagnostic treatment: network activity, developer engagement, institutional flows—all fed into models that learn faster than your average crypto bro during a bull run. The results? Specific price points that'll either look prescient or painfully optimistic come December 2025.
Because nothing says 'solid investment strategy' like letting algorithms predict notoriously volatile digital assets—what could possibly go wrong?
A biotech with a tight focus
That publication marked the initiation of coverage on CG Oncology stock by veteran researcher Guggenheim, in the person of prognosticator Brad Canino. He rated the company's shares a buy at a price target of $90 per share, which is more than double their latest closing price.
Image source: Getty Images.
CG Oncology is a clinical-stage company that, at present, is intensely concentrated on treating one type of cancer -- non-muscle invasive bladder cancer, or NMIBC. According to reports, Canino believes the prospects for successfully developing a drug to treat this are considerable.
He pointed out that there is a large addressable market, and a successful developer could enjoy significant pricing power with an effective treatment. Canino thinks CG Oncology's investigational cretostimogene could be that drug, as it has been demonstrated to be efficacious and SAFE in clinical trials.
Miles to go
As always with biotechs, I have to caution that there is a long and difficult road to success for even the most promising medicines being developed in labs.
CG Oncology has a strong candidate that might just earn Food and Drug Administration (FDA) approval next year (as that's when it'll be reviewed by the regulator). So there's more than a little reason to be optimistic -- albeit cautiously -- on its prospects.
